<DOC>
	<DOCNO>NCT02680977</DOCNO>
	<brief_summary>In low-income area worldwide , patient Parkinson 's disease ( PD ) afford long-term Levodopa therapy . A potential therapeutic option use legume call Mucuna Pruriens var . Utilis ( MP ) , seed high levodopa content ( 5-6 % ) grow tropical area world . MP powder cheap ( total annual cost PD patient : 10-15 US $ ) . The aim study assess efficacy tolerability acute chronic use MP compare standard Levodopa therapy . The primary objective study investigate efficacy acute levodopa challenge use MP comparison levodopa Dopa Decarboxylase Inhibitor ( LD+DDCI ) without ( LD-DDCI ) placebo . The secondary objective investigate safety acute intake MP well efficacy safety chronic intake MP 8-week period comparison usual LD+DDCI home therapy .</brief_summary>
	<brief_title>Mucuna Pruriens Therapy Parkinson 's Disease</brief_title>
	<detailed_description>Background : Levodopa gold standard treatment Parkinson 's disease ( PD ) . However , low-income area worldwide , patient PD afford chronic therapy levodopa . It therefore mandatory identify interventional strategy design ease economic burden pharmacological management PD develop country . A potential therapeutic option use legume call Mucuna Pruriens variant Utilis ( MP ) , seed contain high LD concentration grow spontaneously tropical subtropical area world , include South America , Africa Asia . It consider invasive plant , grow rapidly without particular measure need ensure growth . The cost home preparation MP roast powder negligible easy store long time . LD isolate MP seed first time 1937 concentration therein estimate 4-6 % . MP also know Ayurvedic remedy PD since ancient time . Preliminary data : Published study parkinsonian rat , primate human suggest MP may use improve PD motor symptom without major side effect . In preliminary study , analyze 25 sample MP Africa , Latin America Asia measure content LD anti-nutrients . We find LD concentration roast powder sample consistent previous literature ( median [ Inter-Quartile Range ] 5.3 % [ 5.17-5.5 ] ) find harmful anti-nutrients MP sample . Study population : patient diagnosis idiopathic PD , include sustain response levodopa presence motor fluctuation define predictable wearing-off , unpredictable ON-OFF fluctuation sudden OFF period . Setting : Clinica Ni√±o Jesus , Santa Cruz ( Bolivia ) . This set chosen local neurologist Dr. Janeth Laguna long-term experience MP therapy patient PD ( approximately 10 year ) . She start use MP patient live rural area ask use cheap source LD reduce monthly cost anti-PD therapy . In experience , J.L . never record serious adverse event ( personal communication ) . Preliminary Laboratory Test : The levodopa content powder obtain roast seed Bolivian black ecotype MP test laboratory Milan ( Italy ) find 5.7 % . No alkaloids major antinutrients find . Objectives : The primary objective ass efficacy acute challenge MP roast powder compare Levodopa formulation dopa-decarboxylase inhibitor ( LD-DDCI ) without ( LD+DDCI ) , placebo . Levodopa dose DDCI administer 3.5 mg/kg , Levodopa without DDCI administer equivalent dose . This conversion factor 5-fold , base publish study compare clinical pharmacokinetic Levodopa effect without DDCI previous double blind study MP patient PD . For example , 100mg Levodopa plus DDCI ( either Benserazide Carbidopa ) correspond 500mg Levodopa without DDCI , obtain administration 8.75 gram MP roast powder ( consider 5.7 % Levodopa bolivian ecotype MP ) . Levodopa dose MP plan administer equivalent dose LD+DDCI ( i.e . 5-fold ) , also low dosage 3.5-fold . Design : double-blind , randomize , placebo control , crossover study acute response levodopa-based therapy Duration : 3-6 hour treatment arm . The secondary objective include additional measure efficacy acute intake MP well efficacy safety chronic use MP source levodopa compare optimize home LD+DDCI therapy . This latter part perform completion acute challenge part study . Design : single-blind , randomize , crossover study chronic response levodopa-based therapy . Duration : 8 week per treatment arm plus 3-week dose adjustment period . Initial levodopa-based therapy regimen ( either MP therapy Levodopa/Benserazide ) may adjust period 3 week optimize daily motor status waking hour . After period , patient enter study levodopa daily dose must leave unchanged throughout 16-week course study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Benserazide</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Benserazide , levodopa drug combination</mesh_term>
	<criteria>Clinical diagnosis idiopathic Parkinson 's disease accord United Kingdom Brain Bank criterion , define presence least two cardinal sign disease ( rest tremor , bradykinesia , rigidity ) without know cause parkinsonism . Sustained response levodopa presence motor fluctuation least 1 h every day wake hour , define predictable wearingoff , unpredictable ONOFF fluctuation sudden OFF period . Patients receive optimum LD+DDCI , stable least 30 day baseline assessment . Availability write informed consent Cognitive impairment accord MiniMental State Examination &lt; 26/30 Clinically significant psychiatric illness , include psychosis , major depression addiction disorder ( include compulsive levodopa intake ) . Hoehn Yahr stage 5/5 medicationOFF state Severe , unstable medical condition ( i.e . unstable diabetes mellitus , moderate severe renal hepatic impairment , neoplasms ) Risk pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Mucuna pruriens</keyword>
	<keyword>Levodopa</keyword>
</DOC>